, and all patients had undetectable viral loads. A rapid decrease of 173 cells/mm 3 in the median CD4 + cell count was observed during the first 4 months after HAART was stopped, followed by a slower decrease of 234 cells/mm 3 between months 5 and 20. The decrease in the median CD4 + cell count early after HAART discontinuation was inversely correlated with the increase that occurred during receipt of therapy ( ) and with the count at the time r p Ϫ0.653 of HAART discontinuation ( ). The decrease in the median CD4 + cell count after the fourth month r p Ϫ0.589 without HAART was correlated with the nadir count before HAART initiation ( ) and the increase r p Ϫ0.349 during treatment ( ). The median follow-up duration was 20 months. After 12, 24 , and 36 months of r p Ϫ0.322 observation, 33 patients (71.7%), 22 patients (47.8%), and 16 patients (34.7%), respectively, remained free of therapy. Adverse clinical events were not seen, and all patients who reinitiated HAART responded rapidly.
Conclusion. Selected asymptomatic HIV-infected patients can safely discontinue therapy for prolonged periods of time.
In the early days of the AIDS epidemic, decisions about starting treatment were fairly straightforward, and most experts agreed that therapy should be initiated as early as possible during the infection course [1] . With the advent of methodology to assess plasma HIV RNA load, a threshold of 10,000 copies/mL was proposed as a strong indication for treatment [2] [3] [4] . This threshold was later increased to 30,000 copies/mL and then to 55,000 copies/mL in subsequent revised recommendations by experts of the International AIDS Society-USA [5, 6] [7] . For the latter group, plasma HIV RNA levels 1100,000 copies/mL may be a reason to initiate therapy [7] . The need for flexibility has been imposed by the knowledge of the risk of progression to AIDS, by our present inability to eradicate the latent reservoir of HIV, and by concerns about the long-term safety of therapy, its toxic effects, potential cardiovascular consequences, and the negative impact of fat maldistribution on quality of life [7] [8] [9] . As recommendations have evolved, patients who initiated HAART with CD4 + cell counts 1300 cells/mm 3 might wish to discontinue treatment. Literature about the discontinuation of antiretroviral therapy for people with 300-500 CD4 + cells/mm 3 is limited [10] [11] [12] [13] , and the safety and efficacy of treatment interruption has not been clearly established. The aim of this study was to evaluate the long-term effect of discontinuation of therapy and to assess how asymptomatic HIV-infected patients could safely remain free of therapy.
PATIENTS AND METHODS
Study design and enrollment. The study began in December 1999. Two authors (M.F.G. and M.G.) identified asymptomatic individuals with CD4 + cell counts 1300 cell/mm 3 and HIV RNA levels !70,000 copies/mL who began therapy when they had CD4 + cell counts !500 cell/mm 3 and/or HIV RNA loads 110,000 copies/mL [2, 4] . Patients had been receiving HAART for at least 6 months and had had undetectable viral loads for у4 months at the time of interruption. The purpose of the study and its possible risks and benefits were explained to the patients, and individuals who decided to discontinue therapy provided informed consent to participate. Patients were advised of a possible higher risk of HIV transmission to sexual partners during treatment interruption and were encouraged to follow strict preventive measures during sexual intercourse.
The study was conducted in accordance with the principles of good clinical practice under the guidance of a written protocol. Medical history, physical examination, blood tests, CD4 cell counts, and HIV RNA levels were determined or performed when antiretroviral therapy was started (baseline), when treatment was discontinued, and every 4 months thereafter. The end points were the slope of the CD4 cell count decrease in the absence of treatment and the need for reinitiation of treatment. We also tried to assess the factors associated with a better outcome in the absence of treatment. Criteria for reinitiation of HAART were CD4 + cell count !300 cells/mm 3 , HIV-1 RNA load 1100,000 copies/mL during 2 consecutive visits, onset of systemic symptoms or opportunistic infections, and patient withdrawal of consent. Patients who missed 2 consecutive visits were considered to have reinitiated HAART.
Plasma viral load assay and CD4 + cell count. Plasma HIV RNA levels were determined using the Amplicor HIV-1 Monitor Ultrasensitive Specimen Preparation Protocol Ultra Direct Assay (Roche Molecular Systems), with a limit of quantification of 20 copies/mL. Determinations of plasma HIV RNA load were performed in duplicate [14] . Subpopulations of CD3 + , CD4 + , and CD8 + T cells were determined by means of 3-color flow cytometry using a Facs-Calibur cytometer (Becton-Dickinson) and direct staining with appropriate monoclonal antibodies (Becton-Dickinson).
Genotypic analysis for drug resistance. Genotypic detection of reverse-transcriptase mutations and mutations conferring resistance to protease inhibitors was performed by means of the LIPA assay (Innogenetics) using HIV-1 RNA specimens obtained with the Amplicor method mentioned above. Cox proportional hazards models were used to determine which factors were independently related to a longer time to reinitiation of HAART. In these models, univariate analysis was first used to examine the association between these factors and the time to reinitiation of HAART, and factors with a statistically significant ( ) association were entered into mul-P ! .05 tivariate analyses to analyze their relationship with the study end points. SPSS software, version 11.0 (SPSS), was used.
RESULTS

Demographic characteristics and risk factors.
A total 46 of 75 potential candidates agreed to participate; 35 (76%) were male. The age was years. A total of 65% of the par-41 ‫ע‬ 10.2 ticipants were men who had sex with men, 22% had acquired HIV infection through heterosexual practices, and 13% had abused drugs. Forty-six percent of patients had Centers for Disease Control and Prevention HIV disease category A1 events, and 54% had category A2 events [15] . Eleven patients were coinfected with hepatitis C virus.
Pretreatment CD4 + cell counts and viral loads. The nadir CD4 + cell count was 488 cells/mm 3 (400-631 cells/mm 3 ), with minimum and maximum values of 304 and 1260 cells/mm 3 , respectively. The baseline HIV-1 RNA load was 34,480 copies/ mL (22,700-46,000 copies/mL), with minimum and maximum values of 1100 and 67,900 copies/mL, respectively. Antiretroviral therapy, CD4 + cell count, and viral load at the time therapy was stopped. Thirty-five (76%) patients were receiving a triple combination of drugs that included 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. Twenty-nine (82.8%) Figure 1 . Median CD4 + cell counts and median HIV RNA levels at baseline, at the time treatment was discontinued (stop), and at 4-month intervals thereafter for 46 HIV-infected patients. Bars, interquartile ranges. of these patients had previously received a regimen that included protease inhibitors. Eleven (24%) patients were receiving 2 NRTIs plus 1 protease inhibitor at the time of discontinuation. The duration of antiretroviral therapy before discontinuation was 34 months (19- (12-36 months) .
Evolution of HIV RNA levels and CD4 + T cell counts. Figure 1 shows the median CD4 cell count and HIV RNA level at baseline, at treatment discontinuation, and at follow-up visits 4-36 months after treatment was stopped. The number of patients at each interval is also shown.
A rapid rebound of the viral load to baseline levels occurred after 4 months without therapy, followed by a relatively stable plateau during the rest of the follow-up period. The decrease in the CD4 + cell count occurred in 2 phases after treatment was stopped: an initial, rapid decrease of 173 cells/mm 3 Outcome, reinitiation of HAART, and cost savings. Figure 2 shows the proportion of patients who reinitiated therapy during a follow-up period of 60 months. The observation time was 20 months (8-32 months), with a minimum and a maximum duration of 4 and 60 months, respectively. After follow-up periods of 12, 24, and 36 months, 33 patients (71.7%), 22 patients (47.8%), and 16 patients (34.7%), respectively, remained without therapy. At the time of censoring, 2 patients had been without therapy for 40 months, and 1 each had been without therapy for 44, 48, and 60 months. Patients did not develop adverse clinical events, and progression to AIDS was not observed. Thirty patients (65%) reinitiated HAART because of a CD4 + cell count !300 cells/mm 3 (7 patients), a viral load 1100,000 copies/mL during 2 consecutive follow-up visits (11 patients), or both (5 patients); 4 patients were lost to follow-up, and 3 withdrew consent.
Factors associated with a higher probability of reinitiating therapy were long duration of undetectable viral load during treatment (hazard ratio [HR], 1.065; 95% CI, 1.022-1.109;
) and low CD4 + cell count at the time of therapy P p .003 interruption (HR, 0.998; 95% CI, 0.997-1.000;
). Only P p .048 duration of undetectable viral load remained significant in the multivariate analysis (HR, 1.065; 95% CI, 1.022-1.109; P p ). . 003 Genotypic analysis of HIV strains was done for the 30 patients who reinitiated HAART. All of these patients had wildtype strains, and resistance to antiretroviral drugs was not observed. Patients restarted the same HAART regimen, and after 4 months, the CD4 + cell count increase was 161 cells/mm 3 (85-244 cells/mm 3 ). Twenty-seven patients (90%) had undetectable viral loads after 4 months of HAART. Three patients had viral loads of 66-529 copies/mL, which became undetectable after 8 months of treatment. At the time of writing, the virus loads for all 30 patients remained undetectable.
Patients were without therapy for 992 months, for a mean treatment-free period of 21 months. Because the monthly cost of antiretroviral regimens given to these patients was, on average, i633 (US $791), it was estimated that the hospital pharmacy saved i627,936 (i13,293/patient) because of the reduced number of drugs that were administered.
DISCUSSION
Several studies have documented the present impossibility of eradicating the cellular reservoir of HIV and the considerable viral burden that remains, even during effective antiretroviral therapy [8, 16, 17] . After stopping treatment, a rapid viral load rebound is observed, with increases in the plasma HIV RNA load of ∼0.2 log 10 copies/day, reaching detectable levels within 1-2 weeks after discontinuation of therapy [17, 18] . Most patients experience a rapid decrease in CD4 + cell count after therapy is stopped, which has been ascribed to the redistribution of lymphocytes back into tissues, followed by a slower but progressive decrease [19] [20] [21] . Our findings are in agreement with the most recent observations in which both viral load and CD4 + cell count returned to baseline levels after 4 months without treatment [10] . The loss of CD4 cells occurred in 2 phases: an initial, rapid decay during the first 4 months after treatment was discontinued, followed by a slower decrease during the following months [12] . As shown by others, the main predictor of the slope of the decrease in CD4 + cell count early after stopping treatment was the increase in the CD4 + count during receipt of therapy; therefore, patients with larger CD4 + cell count increases during HAART had larger decreases after discontinuation of therapy [10, 12] . On the other hand, during the second phase (i.e., 14 months after treatment discontinuation), the nadir CD4 + cell count was the main predictor of the CD4 + cell count decrease [12] . These findings agreed with previous observations showing that patients with lower nadir CD4 + cell counts had to resume therapy in a significantly higher proportion and within a shorter period after treatment discontinuation, compared with patients with a higher nadir CD4 + cell count [11, 13] .
Nowadays, the risk of progression to AIDS among patients starting antiretroviral therapy with CD4 + cell counts of at least 200 cells/mm 3 is low, and even advanced immunosuppression can be overcome with HAART [22] [23] [24] . Although the optimal time to start treatment has not yet been determined, it is conceivable that deferral of treatment may be considered for patients with a low risk of progression to AIDS. This study suggests that asymptomatic HIV-infected patients with a low risk of progression to AIDS who started antiretroviral therapy with a CD4 + cell count of 300-500 cells/mm 3 and/or an HIV-1 RNA load !70,000 copies/mL can safely discontinue therapy for prolonged periods. Patients with higher CD4 + cell counts and greater increases in the CD4 + cell count during treatment are the best candidates. Patients with lower CD4 + cell counts when treatment was started were more likely to resume therapy. Fortunately, the latter patients responded to reinitiated therapy before irreversible immunologic damage occurred. Potential benefits of discontinuation of treatment include reduced toxicities, drug-drug interactions, and selection of resistant variants. Because of the unknown durability of the effects of the currently available therapies, it seems reasonable to stop unnecessary treatment. Improvement in the quality of life and significant decreases in pharmacy expenses are other expected benefits. Because of the risk of immunologic deterioration during the period without therapy, patients who have discontinued treatment should be closely monitored.
